Drosophila Models of Proteinopathies: the Little Fly that Could by Rincon-Limas, Diego E et al.
1108  Current Pharmaceutical Design, 2012, 18, 1108-1122
 1873-4286/12 $58.00+.00   © 2012 Bentham Science Publishers
Drosophila Models of Proteinopathies: the Little Fly that Could 
Diego E. Rincon-Limas
1,*, Kurt Jensen
1 and Pedro Fernandez-Funez
1,2,*
1Departments of Neurology and 
2Neurosciences, McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA 
Abstract: Alzheimer’s, Parkinson’s, and Huntington’s disease are complex neurodegenerative conditions with high prevalence character-
ized by protein misfolding and deposition in the brain. Considerable progress has been made in the last two decades in identifying the 
genes and proteins responsible for several human ‘proteinopathies’. A wide variety of wild type and mutant proteins associated with neu-
rodegenerative conditions are structurally unstable, misfolded, and acquire conformations rich in ß-sheets (ß-state). These conformers 
form highly toxic self-assemblies that kill the neurons in stereotypical patterns. Unfortunately, the detailed understanding of the molecu-
lar and cellular perturbations caused by these proteins has not produced a single disease-modifying therapy. More than a decade ago, sev-
eral groups demonstrated that human proteinopathies reproduce critical features of the disease in transgenic flies, including protein mis-
folding, aggregation, and neurotoxicity. These initial reports led to an explosion of research that has contributed to a better understanding 
of the molecular mechanisms regulating conformational dynamics and neurotoxic cascades. To remain relevant in this competitive envi-
ronment, Drosophila models will need to expand their flexible, innovative, and multidisciplinary approaches to find new discoveries and 
translational applications. 
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1. INTRODUCTION 
  A number of human neurodegenerative conditions are associ-
ated with abnormal protein deposition in brain neurons. This group 
of protein misfolding disorders or proteinopathies includes some of 
the most common diseases among the elderly (e.g., Alzheimer’s 
[AD] and Parkinson’s [PD] disease), several dominantly inherited 
diseases (e.g., Huntington’s disease [HD], Spinocerebellar ataxias 
[SCA] 1 and 3), the aggressive amyotrophic lateral sclerosis (ALS) 
or Lou Gehrig’s disease, and the rare and unique Prion diseases 
(PrD). These protein misfolding disorders belong to a larger class of 
neurodegenerative diseases characterized by late onset, progressive 
loss of brain neurons that includes dominantly inherited RNA dis-
eases (e.g., myotonic dystrophy, SCA8 and 10) and recessive loss-
of-function disorders (e.g., Fragile X syndrome, Friedreich’s 
ataxia), among others. The proteinopathies constitute a heterogene-
ous group of brain disorders (and other systemic conditions that 
will not be reviewed here) that includes dominantly inherited disor-
ders (AD, PD, HD, SCAs, ALS, PrD), sporadic (idiopathic) condi-
tions (AD, PD, ALS, PrD) and infectious diseases (PrD). Some of 
the disorders have multiple etiologies, which contributed to the 
identification of the genes and molecular mechanisms that cause 
them. In the familial forms of the diseases, the mutant genes encode 
the proteins that aggregate in the sporadic forms of each disease, 
thus identifying the culprits in all forms of the disease. These pro-
teins become structurally unstable upon mutation (Ataxin1 [Atx1], 
Cu/Zn superoxide dismutase 1), after abnormal proteolytic cleavage 
(Amyloid-ß42 [Aß42], Huntingtin [Htt]) or are naturally unstable in 
their normal state (Prion protein [PrP],  –Synuclein [ –Syn]). Re-
gardless of the origin of the structural perturbations in these pro-
teins, the conformational changes (misfolding) expose hydrophobic 
residues and increase the ß-sheet content (ß-state). The ß-state is 
unstable as a monomer because of the need to hide the exposed 
hydrophobic residues, leading to self-assembly into small, soluble 
aggregates (oligomers). These soluble assemblies are highly toxic 
in cell culture models and are proposed to be the neurotoxic species 
[1, 2]. Over time, oligomers aggregate by a “seeding-nucleation” 
model [3] into larger, insoluble, fibrillar structures that are detected  
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by traditional histo-pathological techniques: amyloid plaques and 
neurofibrillary tangles in AD, Lewy bodies in PD, and nuclear in-
clusions in HD and SCAs. A testament to the complexity of these 
disorders is that two decades of tremendous advances in under-
standing the structural dynamics and biological properties of these 
proteins have provided no disease-modifying therapies.  
  Protein misfolding is mostly an intrinsic property of these 
pathogenic proteins: their amino acid sequences (either wild type or 
mutant) contain the information that makes them structurally unsta-
ble and capable of populating the ß-state [3]. Given the intrinsic 
structural instability and neurotoxicity of these proteins, it is not 
surprising how easy it was to replicate those properties in trans-
genic flies and how popular these disease models have become in 
the last decade. Two breakthrough reports in 1998 paved the way 
by modeling two dominant conditions in flies, HD and SCA3 [4, 5]. 
Several more papers came shortly after from laboratories that 
worked independently on the same idea [6-9], and an explosion of 
papers followed in the next decade (Fig. 1). Here we review some 
of the most important contributions of Drosophila to unraveling the 
molecular mechanisms of neurodegeneration and discuss its future 
applications in gene and drug discovery efforts. 
2. THE MIGHTY LITTLE FLY 
 Drosophila  melanogaster is a small fruit fly with worldwide 
distribution that poses no threat to human health and agriculture. 
What made Drosophila attractive to T.H. Morgan in the early 1900s 
is that fruit flies have a short life cycle (10 days at 25°C) and pro-
duce a large progeny (upwards of 100 eggs per female). The pio-
neering work of Morgan and Sturtevant with these elegant, golden-
colored flies produced the first mutation in 1906, white, which 
eliminated the pigment from the large eyes, and many more muta-
tions followed in the ensuing decades. Many additional reasons 
make Drosophila the model of choice to tackle relevant biological 
problems: access to large collections of mutant strains, sophisti-
cated genetic techniques, multiple approaches for manipulating 
gene expression, easy transgenesis, and compatibility with low- to 
mid-throughput screening [10]. Additionally, Drosophila has been a 
leader in genome sequencing and annotation [11].  
 Drosophila  has been a favored tool for genetic studies for over 
100 years and is an excellent model system to study a variety of 
biological processes, including development, signal transduction, 
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substantial contributions to fundamental questions in neurobiology: 
nervous system organization and function, information integration 
and processing, wiring and physiology of neural circuits, neurode-
generation, and the genetic control of behavior, sleep, memory, 
aggression, mating, and addiction [12]. A transformative moment in 
Drosophila research came with the realization of the extraordinary 
conservation of gene sequence/function with humans. In fact, some 
of the most important genes with key regulatory functions were first 
described in flies [see [12] for historical context], including Ho-
meotic/HOX, decapentaplegic/TGF-ß, Wnt/wingless, Hedge-
hog/Sonic hedgehog. Indeed, over 75% of the human genes impli-
cated in disease display highly significant sequence conservation at 
the protein level with Drosophila genes [13]. This high degree of 
functional conservation suggests that diseases resulting from dis-
ruption of conserved cellular pathways should be easily recapitu-
lated at genetic and molecular levels in fruit flies. 
3. THE EVER-EXPANDING TOOLBOX 
 Drosophila  still maintains a healthy edge over other animal 
models in the ability to manipulate gene expression and function. 
The genetic toolbox in Drosophila is unrivaled due to constant 
innovation and the selfless sharing of ideas and resources [10, 14]. 
This is a brief summary of the most relied upon genetic tools in 
flies. 
 Gene  expression. Following the recombinant DNA revolution 
of the 80s, which introduced the technology for incorporating 
transgenes in flies (always first!) and other animals [15], the early 
90s brought another game changer: the UAS/Gal4 expression sys-
tem. The heterologous UAS/Gal4 system imported from yeast is a 
binary expression system: one strain carries a transgene under the 
control of the UAS (upstream activating sequence) promoter se-
quence, and a second strain expresses the transcription factor Gal4 
[16]. Transgenes are cloned into a freely available vector (pUAST) 
downstream of the UAS, followed by microinjection of embryos 
(now outsourced to commercial services). To induce transgene 
expression, the UAS-transgene strains are combined with strains 
expressing Gal4 under the control of highly diverse promoters 
(from ubiquitous to single cell), offering unparalleled experimental 
flexibility (Table 1). The UAS/Gal4 system is a terrific tool for 
directing the spatial expression of transgenes; unfortunately, it pro-
vides poor temporal control. The introduction of the tripartite 
TARGET (temporal and regional gene expression targeting) system 
finally provided good temporal control to the UAS/Gal4 system, 
thus taking full advantage of the tens of thousand of existing UAS-
regulated transgenes [17]. TARGET introduces a temperature-
sensitive allele of the Gal4 inhibitor Gal80, which regulates gene 
expression by shifting from permissive temperature (19°C, Gal80
TS
active, Gal4 inactive) to restrictive temperatures (30°C, Gal80
TS
inactive, Gal4 active). TARGET has become a wonderful tool for 
manipulating critical processes in adult flies, particularly those 
associated with brain function, without affecting central nervous 
system (CNS) development. 
 Mutant  strains. In addition to the classic mutations generated by 
chemicals and ionizing radiations, transposable elements (P-
elements) have played a key role in the relentless push to mutate 
every gene in the fly genome (Table 1). P-element-mediated gene 
discovery has introduced transposable elements near or inside 65% 
of Drosophila genes, making them available for further modifica-
tion, including excision, in vivo tagging, and enhancer capture for 
Gal4 expression [10, 14]. Also, modified P-elements carrying the 
UAS enhancer with a minimal promoter allows misexpression of 
nearby genes, which have proved very useful in genetic screens 
[18]. Several versions of this transposon have been randomly in-
serted throughout the Drosophila genome, resulting in tens of thou-
sands of invaluable strains stored in various stock centers (Table 1).
Moreover, the Drosophila field has fully incorporated the powerful 
RNA interference (RNAi) technology from C. elegans [19]. Re-
searchers now have access to genome-wide collections of RNAi 
molecules (double stranded RNA) for cell culture assays plus three 
independent genome-wide collections of transgenic flies carrying 
RNAi constructs under the control of UAS (Table 1). P-element 
technology has finally allowed the creation of a genome-wide col-
lection of molecularly defined deletions, an invaluable resource for 
gene mapping.  
 Latest  technologies. The fly genome allows the most sophisti-
cated manipulations of any animal model, from random transposon 
tagging to site-specific transgenesis. Latest efforts have focused on 
making gene targeting more efficient in Drosophila through the use 
of zinc-finger nucleases [20]. Also, recombination-mediated genetic 
Fig. (1). The upward trend of disease model publications using flies. Publications displayed in PubMed with general disease application (red) and those 
relevant to neurodegenerative diseases (blue). The numbers for 2011 are projections based on year-to-date publications. Search parameters: Blue: (neurode-
generative OR neurodegeneration) AND drosophila; Red: (disease OR neurodegenerative OR neurodegeneration) AND drosophila. Search terms were limited 
to the title and abstract to eliminate false positives. This can lead to underestimation of the number of papers (false negatives), but a brief visual analysis con-
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engineering or recombineering, coupled with the bacteriophage 
C31 integrase, has provided a new platform for easy and speedy 
manipulation of DNA fragments larger than 130,000 bases into the 
fly genome [14]. Finally, recent methods for the automated mass-
injection of fly embryos will result in an expanded ability to test 
and use sophisticated P-element vectors and RNAi [21, 22]. This 
area of Drosophila research is very hot and continues to provide 
revolutionary technology every year. 
4. FLY MODELS OF NEURODEGENERATIVE DISORDERS 
  The innovative models of human neurodegenerative diseases 
that appeared between 1998 and 2000 inspired a new field of re-
search and created a whole generation of researchers dedicated to 
understand human neurological diseases using Drosophila. This 
community has produced hundreds of research papers in the last 
few years and is projected to publish more than 100 papers in 2011 
(Fig. 1). Current examples of Drosophila models of neurodegenera-
tive disease include AD, PD, tauopathies, several polyglutamine 
disorders (HD, SCA1, SCA3 [a.k.a. Machado-Joseph disease], Spi-
nobulbar muscular atrophy), ALS, PrD, dystonia, non-coding ex-
pansions (SCA8, myotonic dystrophy), and several recessive disor-
ders, including Fragile-X syndrome and Friedreich’s ataxia, among 
others. These models have been reviewed recently in excellent pa-
pers and the reader should refer to them for more details [23, 24]. 
We next present a brief overview of the proteinopathies and how 
Drosophila has contributed to their understanding. 
4.1. Alzheimer’s disease and Frontotemporal dementias 
  AD is the most prevalent neurodegenerative disorder affecting 
1% of those 65 years old or older and up to 35% of those older than 
85. With the rising life expectancy in advanced economies, AD is 
acquiring the dimensions of an epidemic [25]. AD first manifests by 
short-term memory loss, progressing to loss of executive functions 
and full dementia over several years. Upon autopsy, the AD brain is 
characterized by degeneration of the cortex and hippocampus, and 
by two types of protein deposits: extracellular amyloid plaques rich 
in the Aß42 peptide and intracellular neurofibrillary tangles (NFT) 
containing the microtubule associated protein Tau. According to the 
“amyloid hypothesis”, accumulation of the Aß42 peptide initiates 
the pathogenic cascade in AD, including Tau hyperphosphorylation, 
aberrant cellular signaling and, ultimately, cell death [26]. The 
Aß42 peptide is the result of ß- and  -secretase cleavage of the 
transmembrane Amyloid Precursor Protein (APP). Mutations asso-
ciated with familial AD affect APP and two proteins with  -
Table 1.  Drosophila Resources  
Name Website Features  Content 
Flybase flybase.org 
Genes, alleles, phenotypes, sequence, stocks,
images, movies 
55,000+ gene records from 
500+ Drosophilids 
Bloomington Drosophila Stock Center  flystocks.bio.indiana.edu 
Collect, maintain, and distribute Drosophila 
strains for research 
30,810 stocks, 196,930 lines 
distributed in 2010 
DrosDel  drosdel.org.uk  An isogenic deficiency kit for Drosophila
15,166 total possible dele-
tions 
Drosophila Genetic Resource Center  dgrc.kit.ac.jp/en  Mutants, aberrations, balancers, insertions  17,140 stocks 
Drosophila Species Stock Center, San 
Diego 
stockcenter.ucsd.edu  Diverse array of species  250 species in 1499 stocks 
Drosophila Genomics Resource Center  dgrc.cgb.indiana.edu  Cell lines, clones, and vectors 
135 cell lines, 1,000,000+ 
clones 
Drosophila RNAi Screening Center  flyrnai.org 
dsRNA for cell culture assays, coding and 
non-coding RNAs 
13,900 genes, dsRNA in 62 
assay plates 
Vienna Drosophila RNAi Center 
stockcenter.vdrc.at/ 
control/main 
UAS-dsRNA in flies 
31,896 strains, 13,142 genes 
(93% coverage) 
Berkeley Drosophila Genome Project  fruitfly.org  Sequence data, clones, stocks, libraries  118.4 Mb genome assembly 
MODel organism ENCyclopedia Of 
DNA Elements (modENCODE) 
modencode.org 




Textpresso for Fly  textpresso.org/fly 
Information extracting and processing for fly
literature 
Literature on Fly: Title: 
43186; Abstract: 36029; 
Total: 99179 
The Interactive Fly 
sdbonline.org/fly/aimain/ 
1aahome.htm 
Guide to Drosophila development 
and metazoan evolution 
Atlases, gene listings 
Drosophila Interactions Database  droidb.org 
Protein-protein, TF-gene, miRNA-gene, and 
genetic interactions 
400,031 interactions, 15,201 
genes 
Drosophila Protein Interaction Map 
interfly.med.harvard.edu/ 
index.php 
Unbiased interaction map of the proteome 
based on MS analysis 
3,546 interactions Fly Models of Proteinopathies  Current Pharmaceutical Design, 2012, Vol. 18, No. 8    1111
secretase activity, Presenilin 1 and 2, supporting the hypothesis that 
overproduction of Aß42 initiates AD pathogenesis. Only temporary 
symptomatic treatment for early AD is currently available, but the 
most promising upcoming therapies may be based on immunode-
pletion of specific conformers of Aß oligomers [27]. 
  The first AD-related studies in flies focused on APP and 
showed that overexpression of Drosophila APPL (APP-Like) and 
human APP (Table 2) cause axonal transport defects [28, 29]. This 
axonal dysfunction phenotype was also associated with other dis-
ease-related proteins (mutant Huntingtin), hinting at a common 
mechanism of neurodegeneration in different diseases [30]. Specific 
APP cleavage is key for accumulation of Aß42 and AD pathogene-
sis; interestingly, Drosophila possesses all the components neces-
sary for both amyloid and non-amyloid processing of APP [31, 32]. 
The  -secretase complex is essentially the same in flies and can 
cleave either APP or APPL at the  -site in the transmembrane do-
main [31]. In addition, a Drosophila ß-secretase-like enzyme 
(dBACE) cleaves APPL (but not APP) in the ß-site, leading to the 
production of Aß42, formation of amyloid fibers and neurotoxicity 
[32]. The conservation of the amyloidogenic and non-amyloido-
genic pathways in Drosophila created ideal conditions for further 
uncovering new genetic and pharmacologic regulators of APP 
processing. Although flies do not produce Aß42 naturally, overex-
pression of human APP and BACE combined with Drosophila
Presenilin (Psn) results in Aß42 production and neurotoxicity [33]. 
Using these flies, a ß-secretase inhibitory peptide demonstrated 
increased potency when anchored to the membrane by a sterol moi-
ety [34]. Moreover, known inhibitors of human Presenilins rescue 
the toxicity of triple transgenic flies and induce Notch-related de-
velopmental defects, indicating that these drugs interact with and 
inhibit Drosophila Psn [33, 35]. These observations suggest that 
fruit flies can be used for in vivo validation and toxicity evaluation 
of novel  -secretase inhibitors of high importance for the pharma-
ceutical industry. In addition to these pharmacological applications, 
Drosophila models of AD have been applied to the discovery of 
novel genetic regulators of APP processing. Ubiquilin was origi-
nally identified as a Presenilin-interacting protein with a potential 
contribution to early-onset AD [36, 37], but its functional interac-
tion with other AD genes was ultimately demonstrated in transgenic 
flies. These studies demonstrated that Ubiquilin regulates Psn activ-
ity and uncovered its direct interaction with and regulation of APP 
[38-40]. Finally, recent genetic screens have identified new modifi-
ers of Psn activity that also interact genetically with APP [41, 42]. 
These observations suggest an unexpected level of complexity in 
the regulation of APP processing, expanding the number of poten-
tial targets for AD therapeutics. 
  An alternative approach to the production of Aß42 through the 
amyloidogenic pathway is to directly express Aß42 fused to a sig-
nal peptide for secretion in flies [43-46]. Aß42 induces strong phe-
notypes in several assays, including memory and learning deficits, 
making this model very attractive for uncovering the genetic 
mechanisms of Aß42 neurotoxicity, and for testing drugs with pro-
tective activity. Given the relative ease to generate transgenic ani-
mals, different forms of the Amyloid-ß peptide, including Aß40, 
Aß42, Aß42 with the familial AD Arctic mutation, and Aß42 with 
artificial mutations, have been compared in vivo. Overall, these 
studies confirmed experimentally that Aß42 aggregation propensity 
correlates with neurotoxicity; thus, strategies that prevent Aß42 
aggregation should reduce toxicity [43, 47, 48]. For instance, feed-
ing flies with Congo Red, a dye that binds to amyloids and prevent 
Aß42 fibrillization in vitro, prevents neurotoxicity [45]. In addition, 
compounds that stabilize the -helical conformation of Aß13-26 
also rescue Aß42 toxicity in flies [49]. These strategies make Dro-
sophila a key tool for in vivo testing of promising AD compounds. 
For more details, comprehensive reviews on AD models in flies are 
available in the recent literature [50, 51]. 
  Frontotemporal dementias (FTD) refer to a complex group of 
disorders that present with radical personality changes with in-
volvement of either the frontal or the temporal lobes. FTP are 
mostly sporadic, but one of its forms, frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17), is associated 
with mutations in Tau. This connection explains the role of Tau 
accumulation in other forms of FTD, which collectively receive the 
name of tauopathies. The first fly model of tauopathy was based on 
expression of wild type Tau and mutations linked to FTDP-17 (Ta-
ble 2) [52]. Human wild type and mutant Tau disrupt the eye, in-
duce locomotor dysfunction and shorten lifespan. Similarly, expres-
sion of bovine Tau fused to green fluorescent protein (GFP) caused 
axonal degeneration, while fly Tau disrupted the eye [53, 54], sup-
porting the key role of Tau in neuronal homeostasis. Additionally, 
flies contributed to the identification of Actin cytoskeleton as modi-
fiers of Tau-induced eye phenotype [55, 56]. The neurotoxicity of 
Tau-R406W is associated with accumulation of Actin filaments, 
which is dependent on Tau phosphorylation [57]. Another pathway 
that received attention in Tau neurotoxicity was cell cycle regula-
tion. Tau-R406W aberrantly induces activation of cell cycle pro-
teins through activation of TOR (target of rapamycin), which, in 
turn, mediates Tau neurotoxicity [58]. Finally, several studies on 
Tau have identified the kinases that phosphorylate Ser and Thr 
residues, and the consequence of phosphorylation on Tau confor-
mation and aggregations. This is discussed in more detail in section 
8. 
4.2. Parkinson’s disease 
  Parkinson’s disease is the most prevalent movement disorder, 
affecting four to six million patients worldwide. PD patients suffer 
from tremors, rigidity, bradykinesia (slow movements), and diffi-
culty in balance, symptoms associated with the loss of dopaminer-
gic neurons in the substantia nigra and locus ceruleus of the brain 
[59]. The affected neurons are characterized by cytoplasmic protein 
aggregates known as Lewy bodies and Lewy neurites, which are 
enriched with  –Syn. However, other proteins such as ubiquitin and 
heat shock chaperones are also present, suggesting that these neu-
rons may suffer from abnormal protein quality control mechanisms 
[59, 60]. Although most PD cases are sporadic, genetic defects in 
rare familial cases have provided valuable insights into the patho-
genesis of PD. Notably, three point mutations in  –Syn (A30P, 
E46K and A53T) are associated with autosomal dominant forms of 
PD [60]. Allele multiplication of SNCA, the gene encoding  –Syn, 
also cause familial PD, suggesting that excess of wild type  –Syn
can lead to disease [60]. Inherited forms of PD have been associ-
ated with at least 11 other loci, including Parkin, DJ-1, PINK1, and 
LRRK2/Dardarin (reviewed in [61]). Due to space limitations, we 
will focus on  –Syn proteinopathy in flies. For specialized reviews 
on fly models involving other familial PD genes see [62, 63]. 
 –Syn is a soluble synaptic protein that has been recently pro-
posed to exist natively as a helical tetramer (Bartels et al, Nature, 
2011).  -Syn aggregates easily in vitro and its oligomers are very 
toxic to cultured neurons. However,  –Syn misexpression does not 
induce neurotoxicity in transgenic mice, leaving a big question 
about the role of  –Syn in the neurodegenerative cascade of PD. 
When Feany and Bender showed that normal and mutant forms of 
 –Syn (Table 3) induce selective degeneration of dopaminergic 
neurons, the paper was warmly welcomed [9]. These flies also 
showed locomotor dysfunction as well as  –Syn-rich cytoplasmic 
inclusions reminiscent of Lewy bodies, recapitulating essential 
features of PD. However, other models developed independently 
showed reduced  –Syn neurotoxicity: Bonini and colleagues re-
ported a 50% reduction in dopaminergic cells [64], while other 
authors reported even lower penetrance [65]. Differences in the 
experimental approaches seem to explain these discrepancies [62, 
63]. New methodologies, including semi-automated quantification 
of dopaminergic neurons and increased  –Syn expression through 
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ity in transgenic flies [66, 67]. Additionally, structure-function stud-
ies identified  –Syn regions that play a role in aggregation and 
neurotoxicity in flies [68], while  –Syn variants generated by ra-
tional design demonstrated that mutants with impaired ß-state struc-
ture (surprisingly) exhibit higher neurotoxicity in flies [69]. Based 
on these observations, Drosophila seems to be the best in vivo
model of  –Syn neurotoxicity available, making it a powerful tool 
for gene and target discovery. 
4.3. Huntington’s Disease and other polyQ Disorders 
  Polyglutamine (polyQ) diseases are devastating and incurable 
neurodegenerative conditions with autosomal dominant inheritance 
and worldwide distribution. At least nine polyQ disorders have 
been described, including HD, spinobulbar muscular atrophy 
(SBMA), dentatorubral-pallidoluysian atrophy (DRPLA) and six 
Spinocerebellar ataxias (SCA1, 2, 3, 6, 7 and 17) [70]. PolyQ dis-
orders are linked to the expansion of a glutamine-coding CAG re-
peat within the open reading frame of nine unrelated genes. The 
polyQ expansion perturbs protein stability leading to misfolding, 
aggregation, inclusion formation and extensive neurodegeneration. 
Although these nine polyQ proteins are broadly expressed in the 
CNS, neurodegeneration occurs in selective regions of the brain, 
resulting in clinically distinct neuropathologies. In all these disor-
ders, the mechanisms of neuronal cell death are largely unknown 
Table 2.  AD/Dementia Models in Flies 
Model Transgene  Features  Relevance  References 
APP  dAPPL, hAPP  Full-length APP  Neural differentiation and axon function  [28, 29] 
 APP-swe  APPCT, APPNT 
APP KM670/671NL, 
deletion constructs 
PNS development  [135, 136] 
Nicastrin, Aph-11, dPsn, hPS2, APP-
C99 
In vitro, S2 cells  Description of  -secretase complex  [31] 
  dPsn-WT, N141I, L235P, E280A  Fly  -secretase activity  APP processing, Aß42 toxicity  [33] 
 dPsn+fAD 
dPsn with 14 mutations found in famil-
ial AD 
 -secretase activity  [137] 
dUbqln, hUBQLN1, 
hUBQ-8i 
Fly and two isoforms of human Ubqln  Regulation of  -secretase activity  [38-40] 
 APP-Gal4,  APP-C99-Gal4   -secretase activity sensor  Genetic screen of APP-processing factors  [40, 138] 
  APP, ADAM10/kuz, dBACE 
Fly -secretase, 
-secretase activities 
APP processing  [32] 
  APP-C99  C-terminal 99 a.a.  APP processing, Aß42 neurotox.  [44] 
Aß  Aß40, Aß42  Toxicity of Aß40 vs. Aß42  Aß42 neurotox.  [44] 
  Aß42, E22G (arctic), L17P (synthetic)  Mutant Aß42  Aß42 neurotox.  [45, 48] 
  Pyroglutamate-Aß42  Posttranslational modification  Aß42 aggregation  [139] 
  Aß42x2  Highly expressed  Aß42 neurotox.  [46] 
Tau  bovTau-GFP  Tau reporter  Axonal tracing  [140] 
  hTau, -R406W, -V337M  WT Tau and FTDP-17 mutations  Tau neurotox.  [52] 
  hTau 4R  WT Tau expressed in eye  Tau neurotox.  [93] 
  dTau  Fly Tau  Memory deficits  [141] 
  hTau 3R, 4R 
Tau with 3/ 4 microtubule-binding 
repeats 
Tau neurotox.  [53, 142] 
  hTau-R406W+S2A, S202A  Mutant Tau + S262, 356 or S202 > A  Tau phosphorylation and neurotox.  [104] 
  hTau-T/S>A  14 T/S individually > A  Tau phosphorylation and neurotox.  [105] 
  hTau-AP, -E14  All 14 T/S > A or E  Tau phosphorylation and neurotox.  [58, 106] 
 hTau-S2A,  -S11A 
S at 262 and 356 > A, 
11 S/T > A 
Tau phosphorylation and neurotox.  [107] 
Tau, Aß  Aß, Tau  Tau N4R, Aß42  Aß42, Tau interaction  [57, 143] Fly Models of Proteinopathies  Current Pharmaceutical Design, 2012, Vol. 18, No. 8    1113
and probably involve a variety of gain-of-function activities. To 
help understand these issues, several Drosophila models of polyQ 
disorders have been generated (Table 4). For a more comprehensive 
review of these models, specialized reviews are available [63, 71]. 
 Huntington’s  disease. HD is the most common polyQ disorder 
affecting one in 10,000 individuals, and is characterized by involun-
tary movements (chorea), psychiatric disturbances, dementia, and 
premature death [72]. HD is caused by a CAG expansion (>36) 
within exon 1 of the Huntingtin (Htt) gene. The first Drosophila
model that recapitulated relevant features of HD pathogenesis was 
reported in 1998 [5]. These flies expressed an N-terminal fragment 
of human Htt with variable lengths of polyQ tracts under the control 
of an eye-specific promoter, which led to nuclear inclusions and 
age- and polyQ length-dependent degeneration of photoreceptor 
neurons. Since manipulation of these Htt transgenes was restricted 
to the fly eye, a subsequent model expressing a mutant N-terminal 
fragment (Htt-ex1) capitalized on the flexibility of the UAS/Gal4 
system [73]. Over the last decade, additional models that express 
different N-terminal fragments or full-length Huntingtin under con-
trol of the UAS sequence have appeared (Table 4). Overall, these 
models have made important contributions to understanding the 
molecular pathology of the disease: Htt aggregates sequester other 
expanded polyQ proteins in the cytoplasm, leading to disruption of 
axonal transport [30, 74], while SUMOylation and ubiquitination of 
the expanded Httex1p regulate its neurotoxicity [75]. A new disease 
mechanism was revealed with the full-length Htt fly model, consist-
ing in Ca
2+-dependent increase in neurotransmitter release effi-
ciency, which occurs even before expanded Htt is imported into the 
nucleus [76]. Several other contributions of HD models in gene and 
drug discovery are discussed below. 
  Spinocerebellar ataxias (SCAs). The six known polyQ-related 
SCAs (1, 2, 3, 6, 7 and 17) are the most common cause of domi-
nantly inherited ataxia, accounting for over 50% of ataxia patients 
worldwide [70]. The clinical features of ataxias reflect damage to 
the cerebellum; however, many SCAs are characterized by their 
extracerebellar brain involvement [70]. SCA1 and SCA3 fly models 
were among the first reported [4, 6]. What made them particularly 
attractive despite being rare disorders is that (a) SCAs exhibit a 
purely genetic inheritance pattern and (b) the full-length protein 
(rather than a proteolytic fragment) is involved in pathogenesis, 
which facilitated construct design. SCA1 and SCA3 have played a 
key role in the discovery of disease relevant mechanisms that are 
described below.  
 PolyQ-only  models. Fly models that express pure polyQ repeats 
revealed that expanded polyQ tracts alone are intrinsically cyto-
toxic, form aggregates, and lead to neurodegeneration and prema-
ture death [7, 8]. Interestingly, polyQ toxicity was neutralized by 
protein context [7]. This model was also used to identify genetic 
modifiers of polyQ neurotoxicity [8]; however, given the influence 
of the protein context, most laboratories prefer to use disease-
related polyQ-containing proteins. 
4.4. Amyotrophic Lateral Sclerosis 
  ALS is an incurable, devastating neurodegenerative disorder 
with a rapid disease course. ALS affects 5 out of every 100,000 
people worldwide and is characterized by the selective death of 
upper and lower motor neurons, causing progressive muscle atro-
phy, paralysis, and death within one year of diagnosis. Approxi-
mately 5-10% of ALS cases are familial (fALS), and 20% of these 
patients carry mutations in the gene encoding Cu/Zn superoxide 
dismutase 1 (SOD1), a ubiquitous cytosolic enzyme that protects 
against toxic superoxide radicals. Out the 153 amino acids of 
SOD1, more than 125 distinct mutations have been linked to fALS 
[77]. The mechanisms involved in motor neuron death are largely 
unknown; current hypotheses for ALS pathogenesis include oxida-
tive damage, accumulation of intracellular SOD1-positive aggre-
gates, mitochondrial dysfunction, axonal transport defects, and 
astroglial cell pathology, to name a few [78]. 
  Modeling SOD1-dependent pathology in flies has mirrored 
some of the difficulties experienced by mouse laboratories. For 
instance, overexpression of wild type hSOD1 in motor neurons 
Table 3.  PD and other Proteinopathy Models in Flies 
Model Transgene  Features  Relevance  References 
PD  -Syn-WT, A30P, A53T  fPD  -Syn neurotox.  [9, 64] 
-Syn-WT  Comparative studies of -Syn  Unravels technical issues  [65] 
-Syn-S129A, S129D, YF  S/Y Phosphorylation mutations  Aggregation and neurotox.  [110, 111] 
-Syn71-82, 
1-120, 1-87 
Deletion constructs  Aggregation studies  [68] 
-Syn-WT Highly  expressed  -Syn neurotox.  [67] 
-Syn-WT, A53T, A56P  ØC31 integrase constructs  Aggregation studies  [69] 
PrD  MoPrP-WT, P101L  GSS  PrP misfolding and neurotox.  [86, 87] 
  HaPrP-WT  Sporadic PrD  PrP misfolding and toxicity  [89] 
  RaPrP-WT  Resistant PrP  PrP misfolding and neurotox.  [90] 
ALS  SOD1-WT, G41S  fALS  Longevity studies  [79, 80] 




Longevity studies  [81] 
  SOD1-WT, A4V and G85R 
fALS 
UAS promoter 
Neuronal dysfunction  [82] 1114    Current Pharmaceutical Design, 2012, Vol. 18, No. 8  Rincon-Limas et al. 
dramatically extended lifespan, whereas expression of the fALS 
mutant hSOD1-G41S was not detrimental (Table 3) [79, 80]. 
Moreover, expression of human wild type and mutant SOD1 under 
the control of endogenous dSod regulatory sequences failed to in-
duce neuronal dysfunction in dSod null flies [81]. These results are 
consistent with the lack of motor neuron degeneration upon neuron-
specific expression of mutant SOD1 in transgenic mice. Since 
SOD1 is expressed ubiquitously in the CNS, other cell types such 
as astrocytes may play a role in neuronal degeneration (non-cell-
autonomous toxicity), explaining the difficulties in modeling SOD1 
neurotoxicity in animal models [77]. More recently, another fly 
model of ALS showed that wild type and mutant hSOD1, but not 
dSOD1, induced locomotor dysfunction with abnormal synaptic 
transmission and aggregation of hSOD1, but no apparent neuronal 
loss [82]. Other fly models for non-SOD1 fALS, including those 
expressing TAR DNA-binding protein 43 (TDP43) and vesicle-
associated membrane protein B (VAPB), are extensively reviewed 
elsewhere [63]. 
4.5. Prion Diseases 
  Prion diseases (PrD) are unique among the protein misfolding 
disorders because they can present with sporadic, genetic, and in-
fectious etiologies. These neurodegenerative disorders affect hu-
mans and other mammals and lead to dementia, motor dysfunction, 
and, eventually, death [83]. The Prion protein (PrP) is a membrane-
anchored glycoprotein highly enriched in the brain that has an es-
sential role in the pathogenesis of PrD [84]. PrP undergoes irre-
versible conformational changes from the cellular, –helix-rich 
isoform (PrP
C) to pathological, ß–sheet-rich isoforms (PrP
Sc) that 
are partially resistant to protease degradation. It is well accepted 
that the PrP
C to PrP
Sc conversion is a key event leading to aggresive 
spongiform neurodegeneration and death. Unfortunately, major 
gaps exist in our understanding of how the conformational conver-
sion of PrP occurs and how it ultimately kills neurons.  
  The development of Drosophila models of PrD has been par-
ticularly challenging (Table 3). The first two attempts to induce 
PrP-dependent neuropathology resulted in no obvious degenerative 
effects (reviewed in [85]). These models seemed to accumulate low 
levels of PrP and led the authors to conclude that flies were inade-
quate for studying PrP biology. Later on, flies expressing a different 
PrP mutant associated with a genetic PrD were found to induce 
brain degeneration associated with PrP aggregation [86], and al-
tered synaptic architectures in larval neuromuscular junctions [87]. 
However, aged flies did not accumulate detergent-insoluble or pro-
tease-resistant PrP conformers, thus missing two hallmark features 
of pathogenic PrP. 
  In sporadic Creutzfeldt-Jakob disease (CJD), which accounts 
for 85% of all CJD cases in humans (by far the most common PrD), 
spontaneous misfolding of wild type PrP is responsible for disease 
[88]. To gain insights into the mechanisms involved in the sponta-
neous misfolding of PrP in vivo, we created flies expressing wild 
type PrP from hamster (HaPrP). The hamster is an excellent model 
Table 4.  Polyglutamine Disease Models in Flies 
Model Transgene  Features  Relevance  References 
HD  hHtt-ex1-2Q, -75Q, -120Q  Expressed in the eye  Htt neurotox.  [5] 
  hHtt-ex1-20Q, -93Q  First 90 a.a.  Htt neurotox.  [73] 
  hHtt-1-171-18Q, -138Q  First 171 a.a.  Htt neurotox.  [144] 
  hHtt-1-336-16Q, -128Q  First 336 a.a.  Htt neurotox.  [113] 
  hHtt-1-548-0Q, -128Q  First 548 a.a.  Htt neurotox.  [74] 
  hHtt-ex1-18Q, -48Q, -152Q  EGFP fusions  Htt aggregation and neurotox.  [120] 
  hHtt-ex1-25Q, -46Q, -72Q, -103Q  EGFP fusions  Htt aggregation and neurotox.  [121] 
 hHtt
FL-16Q, -128Q  Full-length  Htt neurotox.and neurobiology  [76] 
SCA1  hSCA1-2Q, -30Q, -82Q  Full-length  Atx1 neurotox.and neurobiology  [6] 
SCA2  hSCA2 and dSCA2  Full-length and deletion constructs  Atx2 function  [145] 
SCA3  hSCA3-27Q, -78Q  C-terminal fragment  Atx3 neurotox.  [4] 
  hSCA3-65Q(NLS), hSCA-77Q(NES)  C-terminal fragment  Atx3 neurotox.and axonal transport  [30] 
  hSCA3-79Q  C-terminal fragment  Atx3 neurotox.  [146] 
 hSCA3
FL-27Q, -78Q, -84Q  Full-length  Atx3 neurotox.  [147] 
SCA7  hSCA7-10Q, -102Q  First 232 a.a.  Atx7 neurotox.  [148] 
DRPL  hAtrophin1-26Q,- 65Q  First 917 a.a  At1 neurotox.  [149] 
SBMA  hAndrogen Receptor-112Q  N-terminal fragment  AR neurotox.  [150] 
 hAndrogen  Receptor-52Q  Full-length  AR  neurotox.  [151] 
PolyQ  20Q, 127Q  HA tagged  polyQ neurotox.  [8] 
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for PrD because it undergoes aggressive disease progression with 
high amounts of pathogenic PrP conformers, suggesting that HaPrP 
is highly prone to populate the ß-state. In young flies, HaPrP exhib-
its properties of native PrP
C; in aged flies, HaPrP acquires PrP
Sc–
like properties, such as resistance to denaturing agents and im-
munoreaction with PrP
Sc-specific conformational antibodies, al-
though it is not resistant to proteases. The accumulation of these 
PrP
Sc–like conformers correlate with severe spongiform degenera-
tion in brain neurons, indicating that the prototypical, infectious 
PrP
Sc conformer is not required to induce spongiform degeneration 
[89]. To further understand how the primary amino acid sequence 
of PrP determines its structural dynamics, we created transgenic 
flies expressing wild type PrP from rabbit (RaPrP), an atypical 
mammal that is resistant to prions [90]. RaPrP does not accumulate 
in PrP
Sc–like conformations and is not neurotoxic, suggesting that 
protective amino acid substitutions prevent the population of the ß-
state [90]. A recent paper identified a RaPrP-specific hydrophobic 
staple that links a loop to helix 3 and increases the conformational 
stability of the globular domain [91, 92]. However, in vivo evidence 
for the protective activity of this and other residues is still missing, 
creating an ideal niche for Drosophila research. This type of func-
tion/structure analyses will help to better understand the rules gov-
erning PrP misfolding and pathogenesis. 
5. MODELING PROTEINOPATHIES IN FLIES: MAKING 
EYE CONTACT  
  The pathogenesis of the proteinopathies involves gain-of-
function mechanisms by either wild type or mutant forms of the 
human protein. Therefore, misexpression of the disease-related 
proteins in flies should be highly toxic to brain neurons, but also 
(potentially) to other tissues and cell types. Following this rationale, 
several laboratories expressed these proteins in different tissues of 
the peripheral nervous system, including the eye and the sensory 
bristles. The compound insect eye has a highly organized lattice 
that is very sensitive to genetic disruption of various biological 
processes, can be easily analyzed under a standard stereoscope, and 
is non-essential for viability. Expression of some disease-related 
proteins in the eye leads to disorganization of the eye lattice or 
rough eye phenotypes, while other proteins do not affect the eye 
(Fig. 2). These phenotypes have been very useful as the basis for 
large scale, unbiased genetic screens and for testing candidate genes 
(see section 8). Critics may argue that the rough eye does not ade-
quately reproduce the neurodegeneration of brain neurons in the 
human disorders; thus, the mechanisms associated with protein 
misfolding toxicity in the eye would be irrelevant to understanding 
the disease. We can deflect these critiques with several arguments. 
(1) While some disease-related proteins induce a rough eye (Atx1-
82Q, Atx3-78Q, Aß42, wild type Tau), others do not (Htt-93Q,  -
Syn, PrP, SOD1) (Fig. 2). Neither gene overexpression nor cellular 
overload explains photoreceptor toxicity; therefore, specific path-
ways must be perturbed to disrupt the eye. (2) Another important 
observation is that when these disease-related proteins affect the 
eye, they induce very different phenotypes: disorganized lattice, 
glassy surface, fused ommatidia, lost pigment, or reduced size (Fig. 
2, B,C,D, G and H). Thus, each protein interferes with different 
pathways/networks in the eye that explain the specific eye perturba-
tions. (3) Interestingly, Aß and Tau show similar rough eye pheno-
types, with reduced size and fusion of ommatidia (Fig. 2, G and H),
suggesting that these two AD genes affect similar path-
ways/networks during eye development. (4) Although mutant Htt 
does not induce rough eye like mutant Atx1 and Atx3, mutant Htt 
induces progressive degeneration of the underlying retina. This 
observation supports the relevance of the protein context in polyQ 
diseases. Finally, (5) the rough eye induced by Aß42 is the same 
whether Aß42 is expressed in photoreceptors (neuron only) or in all 
eye cell types, suggesting that the rough eye is a consequence of 
Aß42 toxicity on photoreceptor neurons, not on the neighboring 
support cells [46]. Regardless of the advantages of using the rough 
eye for rapid screening purposes, it is advisable to develop assays 
that support neurotoxicity to central neurons for secondary screens 
or validation purposes. 
  Another common approach in fly models of proteinopathies is 
to use locomotor activity to assess neuronal dysfunction. In fact, all 
the models described here show progressive locomotor dysfunction, 
including the wild type alleles of  -Syn, hSOD1, and hamster and 
mouse PrP. The typical locomotor test measures the ability of flies 
to climb upward following their innate negative geotaxis, a simple 
assay easy to set up in the lab, although complex software packages 
can also analyze more comprehensive behavioral tasks. These lo-
comotor tests are highly relevant to the pathology of movement 
disorders such as PD, ALS and HD, but they have also been used in 
models of dementias (AD, PrD). How is this locomotor assay rele-
vant to understand the molecular mechanisms of Aß42 neurotoxic-
ity, a peptide that targets primarily the hippocampus and the cortex? 
Although Aß42 induces progressive memory deficits in flies [43], 
these assays are complex and time consuming. Thus, we use loco-
motor dysfunction as surrogate for neuronal dysfunction. Locomo-
tor dysfunction informs us about the ability of any protein to inter-
fere with basic neuronal processes, including cell survival/ apopto-
sis, oxidative stress and mitochondrial metabolism, cytoskeleton 
and axonal transport, synaptic architecture and transmission, etc. 
These cellular activities are essentially the same in all neurons; 
thus, a locomotor phenotype is an easy indicator of a serious neu-
ronal pathology. In addition to being easy, locomotor assays pro-
vide complex information about the underlying cellular pathology. 
Curiously, Aß42 and Htt induce distinct locomotor phenotypes: 
whereas flies expressing Aß42 are unremarkably slow, the HD flies 
exhibit highly uncoordinated movements and shaking, a phenotype 
reminiscent of the chorea of HD patients. Coincidence? Unlikely. In 
fact, this locomotor dysfunction indicates that flies undergo specific 
neurodegenerative changes related to HD pathology, making them 
an excellent system to understand the molecular mechanisms under-
lying HD neurodegeneration. The experimental flexibility provided 
by the locomotor assays allows for fast and efficient characteriza-
tion of new disease models and of potential genetic and pharma-
cologic modifiers of the pathology. Many other assays are available 
for characterizing protein neurotoxicity, including memory and 
learning, longevity/survival, and analyses of specific neuronal loss 
such as dopaminergic neurons in PD models. These assays have 
different applications based on their technical complexity: gene 
discovery efforts require easy-to-score phenotypes (rough eye), 
while testing protective genes or drugs demand higher specificity 
(memory tests, survival of dopaminergic neurons). In any case, the 
availability of multiple assays is a testament to the flexibility of 
Drosophila.
6. PROTEIN AGGREGATION AND THE NEUROTOXIC 
PARTICLE 
  Another key feature of these proteins is their ability to form 
disease-specific assemblies with characteristic cellular distribution. 
So far, Drosophila models have been very good at reproducing 
disease-specific protein dynamics: mutant Atx1, Atx3, and Htt ac-
cumulate in nuclear inclusions (NI) [4-6], whereas both wild type 
and mutant  -Syn accumulate in Lewy body-like cytoplasmic ag-
gregates [9]. In addition, wild type PrP accumulates in detergent-
soluble aggregates in lipid rafts, although some of it is retained in 
the secretory pathway as a consequence of early misfolding [89]. 
Overall, all of these proteins accumulate and aggregate in the right 
subcellular compartment and lead to neurotoxicity, making these 
models powerful tools for understanding in vivo protein dynamics 
and neurotoxicity. However, interesting observations in flies have 
provided relevant cues about the role of protein aggregates in neu-
rotoxicity. Although mutant Atx1, Atx3 and Htt-ex1 form NI, these 
large aggregates may have a protective role as suggested by the 
increase in aggregate size by co-expression of chaperones and Atx1 
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without obvious NI, supporting the role of other conformers in neu-
rotoxicity [76]. Also, wild type and mutant Tau accumulate in neu-
rites [52, 93], but flies do not accumulate NFT, the typical AD and 
FTD aggregates containing hyperphosphorylated Tau [52]. This 
observation suggests that Tau-dependent neurodegeneration does 
not require NFT and supports the role of soluble assemblies in tox-
icity. Similarly, flies expressing HaPrP display extensive vacuolar 
degeneration without accumulation of the protease-resistant PrP
Sc
isoform, suggesting that different PrP isoforms are responsible for 
infection and neurotoxicity [89, 94]. In flies, Aß42 aggregates in 
both extra- and intracellular amyloid aggregates [43], which have 
also been observed in AD patients [95], despite having strong signal 
peptides, suggesting that Aß42 is internalized after secretion. 
Moreover, the intrinsic aggregation propensities of 17 artificial 
mutations in Aß42 (chosen from 798 variants tested in silico) ex-
hibited a strong correlation with their neurotoxicity in flies [47]. 
The exception was a double mutant with the highest predicted ag-
gregation propensity (E22G, I31E). It turns out that this double 
mutant rapidly formed fibrillar aggregates, a state less toxic than 
soluble oligomers and protofibrils. This study demonstrated that 
Aß42 neurotoxicity is tightly regulated by its fibrillation, and that 
both too little and too much aggregation could reduce Aß42 neuro-
toxicity. Overall, Drosophila models of proteinopathies have pro-
vided important clues for uncovering the connection between pro-
tein aggregation and neurodegeneration. 
7. LIMITATIONS: THE ELEPHANT-SIZE FLY IN THE 
ROOM 
  Disclaimer: Fly models of human diseases are just that, models. 
The anatomy and physiology of invertebrates are significantly dif-
ferent from those of humans, which impose constraints on translat-
able research. In the case of neurodegenerative diseases, an obvious 
limitation of fly models is the reproduction of physiological disease 
conditions: fly models cannot replicate the decades-long progres-
sion of the disease nor the regional- and neuronal-specific brain 
pathology. Moreover, fly models are based on gene misexpression, 
in which transgenes are not regulated by endogenous promoters. 
These critiques are legitimate, but the same could be said about 
many popular mouse models based on transgene overexpression 
(e.g., SCA1-B05, HD-R6/2, AD-Tg2576). Although several knock-
in mouse models with late onset and slow progression have been 
generated in the last decade, they have not eliminated the use of 
misexpression models because the latter have more robust pheno-
types and are easier to use for discovery purposes. Likewise, Dro-
sophila models are still relevant towards uncovering disease 
mechanisms, target discovery, and other innovative applications 
(see below).  
  But, is the fly still a relevant model of neurodegenerative disor-
ders? Has it become unfashionable? The evidence says no: the 
number of publications continues on an upward trend (Fig. 1) and 
many of those papers continue to appear in high-quality journals. 
However, both public and private funding agencies seem reluctant 
to fund studies in Drosophila, moving away from basic or explora-
tory research projects. This may be a shortsighted approach since 
some of the most spectacular discoveries with human health appli-
cations have come from basic research (RNAi in worms, circadian 
rhythm in flies). Ultimately, it is our responsibility to focus our 
research towards relevant, innovative, and/or translational areas, 
and to explain better the relevance of our research to the general 
public.  
8. ROBUST PHENOTYPES LEAD TO GENETIC SCREENS 
  Fly models of proteinopathies exhibit neuronal dysfunction, 
neuronal loss, and protein aggregation. These phenotypes have been 
described in many disease models, including mice and cultured 
cells. What, then, makes Drosophila relevant? Without a doubt, 
Drosophila stands out because of the ability to perform genetic 
screens for modifiers of neurotoxicity in a cost- and time-efficient 
manner. Fruit flies are an excellent model system for in vivo testing 
of small sets of interesting genes (candidate approach) by taking 
advantage of existing loss-of-function or overexpression alleles, or 
Fig. (2). Disruption of the fly eye by expression of amyloidogenic proteins. (A-H) Microphotographs of the Drosophila compound eye. Higher magnifica-
tions show a detail from scanning electron microphotographs (artificially colored). (A) Control eye showing normal pigmentation and organization of the 
ommatidia. (B) Flies expressing Atx1-82Q show highly disorganized (glassy), depigmented eyes, with necrotic spots. High magnification shows poorly differ-
entiated ommatidia with small bristles (arrow). (C) Flies expressing Atx3-78Q show disorganized and depigmented eyes with normal bristles. (D) Flies ex-
pressing Htt-93Q have normal eye structure at day 1 (left), but the underlying retina degenerates by day 20, resulting in patchy depigmentation (right). (E and 
F) Flies expressing 3 copies of wild type -Syn (E) or wild type hamster PrP (F) have normal eye structure and pigmentation. (G and H) Flies expressing 
Aß42 (G) or wild type Tau (H) have small, disorganized, bumpy eyes resulting from fusion of ommatidia (arrows). Fly Models of Proteinopathies  Current Pharmaceutical Design, 2012, Vol. 18, No. 8    1117
by creating new transgenic flies in less than 10 weeks. Moreover, 
flies have also been used for unbiased screens of large sets of mu-
tants that allow the identification of new genes and molecular 
pathways involved in disease pathogenesis. Here, the eye pheno-
types have played a fundamental role because the easy analysis of 
the rough eye under the dissecting microscope allows testing of 
hundreds of genes per week and over a thousand genes per month. 
Other phenotypes such as reduced survival or locomotor dysfunc-
tion are also compatible with large genetic screens, although they 
are more time-consuming and may require the use of advanced 
engineering and software. The more time-consuming the task, the 
fewer conditions (genes) can be tested. That explains why the larg-
est modifier screens have been performed in the eye [6, 55, 96, 97]. 
These are a few examples of the contributions of fly genetics to 
uncovering disease mechanisms. 
  Coping with protein aggregation: Hsp70. Several amyloi-
dogenic proteins aggregate inside the cell, suggesting a role for 
protein quality control mechanisms in pathogenesis. Cell culture 
studies demonstrated the role of molecular chaperones, particularly 
the Heat shock protein 70 (Hsp70), in Atx1 aggregation and neuro-
toxicity [98]. However, in vivo evidence for this protective activity 
was missing. N. Bonini showed that overexpression of an inducible 
isoform of human Hsp70 suppressed the rough eye phenotype and 
Atx3 aggregation in flies [99]. In an unbiased genetic screen, we 
found that the Hsp70 co-chaperone Hsp40 suppressed the rough eye 
of Atx1 [6]. This ability of molecular chaperones to suppress 
pathogenic protein aggregation and neurotoxicity was later ex-
panded to include other disease models. For instance, co-expression 
of Hsp70 and  –Syn alleviated dopaminergic neuronal loss, while 
disruption of endogenous chaperone function enhanced neuropa-
thology [64]. Not surprisingly, Hsp70 later showed the ability to 
block Atx1 and  –Syn aggregation in transgenic mice [100, 101]. 
Trying to extend this protective activity to extracellular amyloids, 
we next wondered if Hsp70 could also reduce misfolding of HaPrP, 
a membrane anchored protein. Interestingly, in flies expressing 
HaPrP, Hsp70 accumulated in the lipid rafts (a highly specialized 
membrane domain) and reduced misfolding and neurotoxicity of 
HaPrP, uncovering a new ability for Hsp70 in preventing misfold-
ing of an extracellular protein [89]. These observations illustrate the 
value of the chaperone system and its implications in the design of 
rational therapeutic approaches for several proteinopathies (see 
below). 
  Protein misfolding in the ER: XBP1. Protein misfolding in the 
ER and the secretory pathway induces the unfolded protein re-
sponse (UPR), which differs significantly from the response to 
misfolded proteins in the cytoplasm and nucleus. The UPR consists 
in the activation of three independent pathways (PERK, IRE1 and 
ATF6) that function to reduce protein synthesis and elimination of 
misfolded proteins in the ER. One of the UPR branches consists on 
the ER stress sensor IRE1 and its downstream effector X-box bind-
ing protein 1 (XBP1), a transcriptional regulator that induces the 
expression of ER chaperones and other factors that reduce protein 
misfolding in the ER [102]. AD brains show signs of ER stress, as 
indicated by the activation of two sensors and several downstream 
effectors; however, the protective role of XBP1 and other ER 
stress-response pathways in AD had not been demonstrated in vivo.
We recently described that flies expressing a bi-cistronic Aß42 
construct induce ER stress and activation of XBP1 [46]. Moreover, 
XBP1 overexpression rescues and XBP1 loss-of-function enhances 
Aß42 rough eye phenotype. This protective activity was mediated 
by the reduction in ryanodine calcium channels in the ER, thus 
preventing the release of pro-apoptotic levels of calcium in the 
cytoplasm. Interestingly, many proteinopathies activate ER stress 
regardless of the localization of the misfolded conformers, suggest-
ing that ER homeostasis may be affected during neuronal degenera-
tion [103]. 
  Posttranslational modifications: Phosphorylation. A recurrent 
theme in proteinopathies is the role of post-translational modifica-
tion, in particular phosphorylation, in protein aggregation and neu-
rotoxicity. The AD brain contains NFT in which Tau is hyperphos-
phorylated. Tau is a long protein with 79 putative Ser/Thr phos-
phorylation sites, and Tau phosphorylation increases aggregation 
and recognition by disease-specific, conformational antibodies. 
Drosophila has played a key role in the in vivo determination of 
many phosphorylation sites. Genetic analysis demonstrated that 
Cdk5 and GSK-3 were Tau kinases that regulate Tau aggregation 
and neurotoxicity [55, 93]. Also, modification of the phosphoryla-
tion sites showed their differential contribution to Tau aggregation 
and neurotoxicity. Whereas the Ser-Pro/Thr-Pro sites seemed to 
work in concert (mutating up to five sites had no significant effect, 
but mutating all 14 sites dramatically increased Tau aggregation), 
the non Ser-Pro sites S262 and S356 played critical roles in Tau 
aggregation by promoting the phosphorylation of Ser-Pro/Thr-Pro 
sites [57, 104-107]. Along the same line, Atx1 and  –Syn phos-
phorylation also proved relevant in neuropathology. In vitro evi-
dence indicated that Atx1 phosphorylation by Akt1/PKB at S776 
promoted binding of 14-3-3, aggregation, and neurotoxicity [108]. 
Reduced Akt1 function suppressed the rough eye of Atx1 flies, 
while a S776A substitution in mice reduced Atx1 toxicity, demon-
strating the functional relevance of Atx1 phosphorylation [108, 
109]. Finally,  –Syn phosphorylation at S129 and T125 exhibited 
opposing effects, the first being neurotoxic and the second neuro-
protective, suggesting that  –Syn toxicity depended on a balance 
between these two modifications [110, 111]. Thus, these studies 
played a critical role in identifying how phosphorylation contributes 
to the generation of the neurotoxic isoform, a key piece of informa-
tion for the rational design of neuroprotective compounds. 
 Unbiased  screens. If candidate pathways have found in Droso-
phila the ideal in vivo system for fast functional tests, unbiased 
genetic screens have expanded our understanding of the molecular 
mechanisms underlying protein misfolding and neurodegeneration. 
Genetic screens provide the means for unbiased gene discovery 
without prior knowledge of the involved pathways. Seminal contri-
butions include the confirmation that protein quality control 
mechanisms, including molecular chaperones and protein degrada-
tion, play important roles in polyQ neurotoxicity [6]. More impor-
tantly, genetic screens served a unique role towards identifying 
novel pathways implicated in Atx1 and Atx3 neurotoxicity, includ-
ing RNA metabolism, cellular detoxification, and transcriptional 
regulation [6, 96]. Not surprisingly, several kinases and phospha-
tases were identified as modifiers of Tau toxicity in the fly eye [55]. 
On the other hand, genetic modifiers of Aß42 implicated the secre-
tory pathway, cholesterol homeostasis and copper transport in its 
neurotoxicity [97]. Thus, four genetic screens based on gene misex-
pression using the same collection of random insertions identified 
very different modifiers, revealing the unique mechanisms of neu-
rotoxicity activated in each model. In addition, a loss-of-function 
screen identified the role of innate immunity and inflammation 
pathways in Aß42 neurotoxicity [112]. By testing collections of 
genetic modifiers of one model against other models, common and 
distinct mechanisms of pathogenesis can be identified [55, 97, 113]. 
Other key findings show that polyQ expansions in Atx1 contribute 
to gain- and loss-of-function mechanisms by specific promo-
tion/disruption of endogenous protein complexes [114]. Interest-
ingly, interaction of Atx1 and Atx3 with other proteins bearing 
polyQ revealed that the activity of Atx2 (SCA2) is critical for 
SCA3 and SCA1 pathogenesis [115, 116]. A comprehensive list of 
genetic pathways and modifiers of polyQ diseases can be found 
elsewhere [117]. 
 Complex  screens. Important contributions to the field of target 
discovery have come from combining high throughput screening 
(HTS) in a variety of platforms with in vivo validation in flies. For 
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down assays with genetic manipulation of an HD fly model led to 
the identification of several Htt-interacting proteins that were 
known modifiers of neurodegeneration [118]. Another screen com-
bining biochemical approaches with fly genetics identified three 
matrix metalloproteases as modifiers of Htt proteolysis and toxicity 
[119]. More recently, genome-wide RNAi screens for modifiers of 
Htt aggregation in vitro combined with validation in fly models, 
identified new regulators of Htt aggregation and toxicity, including 
genes related to nuclear transport, nucleotide processing, and sig-
naling [120, 121]. A different approach consists in identifying aber-
rant pathways through gene expression analyses (microarrays). 
Expression of Aß42 in flies led to significant changes in the expres-
sion of oxidative stress genes and genetic tests confirmed the role of 
the iron-binding protein Ferritin and Catalase as strong suppressors 
of Aß42 neurotoxicity [122]. Given the lack of robust phenotypes in 
 –Syn flies, genetic screens have not been possible with this model. 
However, combination of a primary genetic screen in a yeast model 
of  –Syn aggregation with subsequent validation in a fly model of 
PD led to the identification of Rab guanosine triphosphatase 1 
(Ypt1p/Rab1) as a strong suppressor of dopaminergic cell death 
[123]. This suppression was further confirmed in primary cultures 
of mammalian dopaminergic neurons, highlighting the value of 
simple model systems in the gene discovery process.  
9. THE FLY PHARMACY  
  During the last 20 years, drug research has experienced dra-
matic changes resulting from newer technologies that include ge-
nomics and proteomics, structural biology, informatics, automated 
imaging, microfluidics, and robotics. Biotechnology companies 
have combined these emerging technologies to design robust HTS 
methods for drug discovery. Despite these technological advances, 
effective new drugs come out at a slow rate due to three major limi-
tations: (1) current HTS methods rely mostly on the availability of a 
short list of validated targets; (2)  inability to reproduce human 
pathogenic mechanisms in vitro; and (3) inefficacy of hits when 
tested in rodent models. To bypass these limitations, efforts have 
been directed to screen chemical libraries in simple model organ-
isms, where complex biological processes can be studied in the 
context of intact living systems. In this regard, Drosophila holds 
tremendous potential in pharmacological research [124, 125]. A 
considerable amount of FDA-approved drugs act on receptors or 
downstream effectors of major signal transduction pathways con-
served in flies and humans, including those for Wnt/wingless, 
Hedgehog, TGF-ß, Notch, Ras/MAPK and insulin. The availability 
of several fly models of human diseases may facilitate testing of 
large compound libraries for the few hits that can revert, prevent, or 
delay neurotoxicity. Here, we provide a perspective on how Droso-
phila can complement ongoing efforts in drug development. 
  How to drug a fly. Compounds can be easily provided to larvae 
or adult flies by mixing them with the food or in a sugary solution 
placed in a small Whatman paper from which starved flies will 
drink. Using these strategies, administration of 4-phenylbutyrate 
throughout adulthood extended lifespan, while compounds that alter 
dopamine levels modified aggressive behaviors [126]. In other 
cases, vaporized chemicals such as cocaine or ethanol allowed the 
simultaneous treatment of large groups of flies, making this method 
suitable to automation and HTS [126]. However, determination of 
the actual inhaled dose and the vaporization of active compound 
can be limiting factors. An alternative approach, which offers better 
control over administration of pharmacological compounds, is di-
rect intra-abdominal or intra-thoracic injection [127]. Although this 
procedure requires advanced skills and is more laborious, it allows 
a precise delivery of compounds under the microscope. Interest-
ingly, microfluidic devices coupled with computer-controlled injec-
tion systems have been recently developed to inject fly embryos 
[21, 22]. These efforts emphasize the interest of the Drosophila
community for achieving bona fide HTS conditions. 
  From genes to targets: the hit list. Drosophila models of prote-
inopathies have contributed to the development of novel therapeutic 
approaches [71]. For instance, a seminal work reported that the 
polyQ domain of Htt directly binds the acetyltransferase domains of 
Creb-Binding Protein and p300/CBP-associated factor, resulting in 
reduced histone acetylation and changes in gene expression. To 
compensate for this, flies were treated with histone deacetylase 
(HDAC) inhibitors (trichostatin A and suberoylanilide hydroxamic 
acid), which reversed Htt neurotoxicity [73]. Other important con-
tributions to the suppression of Htt neurotoxicity include the mTOR 
inhibitor rapamycin (autophagy) [128], the inhibition of transgu-
latminase 2, a transcriptional repressor overexpressed by mutant 
Htt, with ZDON [129], ERK activation by polyphenols [130], and 
Meclizine, an FDA-approved drug with anti-histaminergic activity, 
that also suppresses mitochondria respiration and reduces oxidative 
stress [131]. Inhibitors of Sirtuin 2, a member of the histone deace-
tylase family of proteins, rescued  –Syn-dependent loss of dopa-
minergic neurons [132] and also showed neuroprotection in Htt 
flies [133]. Another example of the gene-to-drug transition is the 
rescue of Atx3 and  –Syn toxicity by Hsp70. The pharmacologic 
strategy to stimulate Hsp70 expression consists on inhibiting 
Hsp90, which acts as a negatively regulator of the heat-shock re-
sponse. This approach worked by feeding flies the Hsp90 inhibitor 
geldanamycin, which suppressed  –Syn neurotoxicity [134]. Since 
geldanamycin is very toxic, a new generation of Hsp90 inhibitors 
with improved activity and lower toxicity has been developed, in-
cluding 17-AAG, with potential uses in cancer and neurodegenera-
tive diseases. Taken together, these studies illustrate the potential of 
flies in the discovery and validation of neuroprotective compounds. 
10. DROSOPHILA GOES BIOTECH 
  Several pharmaceutical and biotech companies have embraced 
fruit flies in their research programs. For instance, Exelixis Inc. 
created an impressive collection of gene disruption mutants for use 
in target identification, while Curagen Corporation generated a 
comprehensive protein interaction database of fly proteins. Simi-
larly, Aktogen Limited aims to accelerate the discovery of drug 
targets for the treatment of neurodegenerative and neuropsychiatric 
disorders using flies. Helicon Therapeutics is exploiting an array of 
proprietary technologies from Cold Spring Harbor Laboratory to 
identify fly genes that control memory, and Medros grows fruit flies 
in a standard 96-well format combined with robotics to screen for 
drugs against human chronic diseases. EnVivo Pharmaceuticals was 
founded in 2001 to conduct pharmacological screens in fly models 
of human neurodegenerative disorders using high-speed cameras 
and a proprietary software known as PhenoScreen. This effort was 
later transformed into optimized, drug screen services with fly 
models of neurodegeneration now offered by Vitruvean LLC to 
pharmaceutical companies and academic labs. Thus, the opportu-
nity to request drug screens with the library of choice may contrib-
ute significantly to the drug discovery process in the years to come. 
11. CONCLUSIONS 
 Drosophila models of proteinopathies have provided some of 
our earliest insights into the mechanisms leading to neuronal cell 
death. The ability to manipulate the fly genome in a flexible and 
time-efficient manner, along with an extensive range of genomic 
resources and genetic tools, allows the study of neurodegenerative 
processes at a level of resolution not possible in more complex 
organisms. Thus, fly geneticists are in a unique position to address 
relevant questions in neurodegenerative diseases, such as: Which 
are the molecular mechanisms triggering the accumulation of dis-
ease-related conformations? What is the identity of the neurotoxic 
conformer(s) in each disease? Which are the pathogenic cascades 
leading to neurodegeneration? How do environmental factors and 
susceptibility genes contribute to neurodegenerative disorders? The 
extensive genetic arsenal of Drosophila, combined with a century 
of genetic knowledge, will be instrumental to answer these funda-Fly Models of Proteinopathies  Current Pharmaceutical Design, 2012, Vol. 18, No. 8    1119
mental questions and to pose new hypotheses in the years to come. 
It will be interesting to see how new technologies, including next-
generation sequencing, proteomics, metabolomics, in vivo imaging, 
and single cell analysis, will be utilized in flies to develop a more 
integrated understanding of the cellular perturbations induced dur-
ing neurodegeneration.
  On the other hand, Drosophila is gaining momentum as a plat-
form for therapeutics. This is because, after spending hundreds of 
millions on R&D, pharmaceutical firms discover that promising 
compounds are ineffective in clinical trials or are toxic in humans. 
Therefore, inclusion of model organisms in the initial stages of drug 
discovery is crucial to validate hits and exclude compounds with 
unfavorable properties. Unfortunately, in vivo studies are usually 
performed after lead optimization due to the complexity of rodent 
manipulation, and the relative high number of preliminary hits. The 
pharmacological susceptibility of fly models and the technological 
advances described above illustrate their potential for rapid and 
inexpensive drug evaluation under HTS conditions. Moreover, the 
ability to conduct large-scale genetic screens represents a unique 
opportunity to identify relevant targets. While flies cannot replace 
the need for testing in rodent models, the studies described here 
highlight their potential to speed up the drug discovery process. 
Given the successful multidisciplinary efforts of Drosophila re-
searchers to identify neurodegenerative targets and pathways (that 
would be missed by more conventional approaches), we augur more 
significant contributions in the next decade. Therefore, the future 
looks bright for Drosophila as an instrument for genetic and phar-
macological discovery in neurodegenerative proteinopathies. 
ABBREVIATIONS 
A42  =  Amyloid beta peptide 
AD =  Alzheimer’s  disease 
ALS  =  Amyotrophic lateral sclerosis 
APP  =  Amyloid precursor protein 
Atx =  Ataxin 
Psn =  Drosophila  Presenilin 
DRPL =  Dentatorubral-pallidoluysian atrophy 
GFP  =  Green fluorescent protein 
HD =  Huntington’s  disease 
HTS =  High-throughput  screen 
Htt =  Huntingtin 
PD =  Parkinson’s  disease 
PrD =  Prion  disease 
PrP =  Prion  protein 
SBMA =  Spinobulbar  muscular  atrophy 
SCA =  Spinocerebellar  ataxia 
SOD1  =  Superoxide dismutase 1 
Syn =  Synuclein 
UAS =  Upstream  activator  sequences 
CONFLICT OF INTEREST 
  The authors declare that they have no competing financial in-
terests. 
ACKNOWLEDGEMENTS 
  We apologize for the inability to cite all the excellent contribu-
tions in this field. We thank Larry Marsh, Nancy Bonini and 
George Jackson for the Htt, SCA3, and Tau flies and members of 
our laboratories for helpful suggestions and discussions. This work 
was supported by the NIH grant DP2OD002721 to P.F.-F. 
REFERENCES
[1] Glabe CG, Kayed R. Common structure and toxic function of 
amyloid oligomers implies a common mechanism of pathogenesis. 
Neurology 2006: 24; 66(2 Suppl 1): S74-8. 
[2] Haass C, Selkoe DJ. Soluble protein oligomers in 
neurodegeneration: lessons from the Alzheimer's amyloid beta-
peptide. Nat Rev Mol Cell Biol 2007; 8(2): 101-12. 
[3] Morales R, Green KM, Soto C. Cross currents in protein misfolding 
disorders: interactions and therapy. CNS Neurol Disord Drug 
Targets 2009; 8(5): 363-71. 
[4] Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded 
polyglutamine protein forms nuclear inclusions and causes neural 
degeneration in Drosophila. Cell 1998; 93(6): 939-49. 
[5] Jackson GR, Salecker I, Dong X, et al. Polyglutamine-expanded 
human huntingtin transgenes induce degeneration of Drosophila 
photoreceptor neurons. Neuron 1998; 21(3): 633-42. 
[6] Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, et al.
Identification of genes that modify ataxin-1-induced 
neurodegeneration. Nature 2000; 408(6808): 101-6. 
[7] Marsh JL, Walker H, Theisen H, et al. Expanded polyglutamine 
peptides alone are intrinsically cytotoxic and cause 
neurodegeneration in Drosophila. Hum Mol Genet 2000; 9(1): 13-
25. 
[8] Kazemi-Esfarjani P, Benzer S. Genetic suppression of 
polyglutamine toxicity in Drosophila. Science 2000; 287(5459): 
1837-40. 
[9] Feany MB, Bender WW. A Drosophila model of Parkinson's 
disease. Nature 2000; 404(6776): 394-8. 
[10] Matthews KA, Kaufman TC, Gelbart WM. Research resources for 
Drosophila: the expanding universe. Nat Rev Genet 2005; 6(3): 
179-93. 
[11] Adams MD, Celniker SE, Holt RA, E et al. The genome sequence 
of Drosophila melanogaster. Science 2000; 287(5461): 2185-95. 
[12] Bellen HJ, Tong C, Tsuda H. 100 years of Drosophila research and 
its impact on vertebrate neuroscience: a history lesson for the 
future. Nat Rev Neurosci 2010; 11(7): 514-22. 
[13] Bier E. Drosophila, the golden bug, emerges as a tool for human 
genetics. Nat Rev Genet 2005; 6(1): 9-23. 
[14] Venken KJ, Bellen HJ. Transgenesis upgrades for Drosophila 
melanogaster. Development 2007; 134(20): 3571-84. 
[15] Rubin GM, Spradling AC. Genetic transformation of Drosophila 
with transposable element vectors. Science 1982; 218(4570): 348-
53. 
[16] Brand AH, Perrimon N. Targeted gene expression as a means of 
altering cell fates and generating dominant phenotypes. 
Development 1993; 118(2): 401-15. 
[17] McGuire SE, Roman G, Davis RL. Gene expression systems in 
Drosophila: a synthesis of time and space. Trends Genet 2004; 20: 
384-91. 
[18] Rorth P. A modular misexpression screen in Drosophila detecting 
tissue-specific phenotypes. Proc Natl Acad Sci U S A 1996; 93(22): 
12418-22. 
[19] Mohr S, Bakal C, Perrimon N. Genomic screening with RNAi: 
results and challenges. Annu Rev Biochem 2010; 79: 37-64. 
[20] Carroll D, Beumer KJ, Trautman JK. High-efficiency gene 
targeting in Drosophila with zinc finger nucleases. Methods Mol 
Biol 2010; 649: 271-80. 
[21] Cornell E, Fisher WW, Nordmeyer R, et al. Automating fruit fly 
Drosophila embryo injection for high throughput transgenic studies. 
Rev Sci Instrum 2008; 79(1): 013705. 
[22] Zappe S, Fish M, Scott MP, Solgaard O. Automated MEMS-based 
Drosophila embryo injection system for high-throughput RNAi 
screens. Lab Chip 2006; 6(8): 1012-9. 
[23] Hirth F. Drosophila melanogaster in the study of human 
neurodegeneration. CNS Neurol Disord Drug Targets 2010; 9(4): 
504-23. 
[24] Lu B, Vogel H. Drosophila models of neurodegenerative diseases. 
Annu Rev Pathol 2009; 4: 315-42. 
[25] Alzheimer'sAssociation 2010 Alzheimer's disease facts and figures. 
Alzheimer's and Dementia 2010; 6: 158-94. 
[26] Crews L, Masliah E. Molecular mechanisms of neurodegeneration 
in Alzheimer's disease. Hum Mol Genet 2010; 19(R1): R12-20. 
[27] Wisniewski T, Konietzko U. Amyloid-beta immunisation for 
Alzheimer's disease. Lancet Neurol 2008 Sep; 7(9): 805-11. 1120    Current Pharmaceutical Design, 2012, Vol. 18, No. 8  Rincon-Limas et al. 
[28] Torroja L, Chu H, Kotovsky I, White K. Neuronal overexpression 
of APPL, the Drosophila homologue of the amyloid precursor 
protein (APP), disrupts axonal transport. Curr Biol 1999; 9(9): 489-
92. 
[29] Gunawardena S, Goldstein LS. Disruption of axonal transport and 
neuronal viability by amyloid precursor protein mutations in 
Drosophila. Neuron 2001; 32(3): 389-401. 
[30] Gunawardena S, Her LS, Brusch RG, et al. Disruption of axonal 
transport by loss of huntingtin or expression of pathogenic polyQ 
proteins in Drosophila. Neuron 2003; 40(1): 25-40. 
[31] Takasugi N, Tomita T, Hayashi I, et al. The role of presenilin 
cofactors in the gamma-secretase complex. Nature 2003; 
422(6930): 438-41. 
[32] Carmine-Simmen K, Proctor T, Tschape J, et al. Neurotoxic effects 
induced by the Drosophila amyloid-beta peptide suggest a 
conserved toxic function. Neurobiol Dis 2009; 33(2): 274-81. 
[33] Greeve I, Kretzschmar D, Tschape JA, et al. Age-dependent 
neurodegeneration and Alzheimer-amyloid plaque formation in 
transgenic Drosophila. J Neurosci 2004; 24(16): 3899-906. 
[34] Rajendran L, Schneider A, Schlechtingen G, et al. Efficient 
inhibition of the Alzheimer's disease beta-secretase by membrane 
targeting. Science 2008; 320(5875): 520-3. 
[35] Micchelli CA, Esler WP, Kimberly WT, et al. Gamma-
secretase/presenilin inhibitors for Alzheimer's disease phenocopy 
Notch mutations in Drosophila. Faseb J 2003; 17(1): 79-81. 
[36] Mah AL, Perry G, Smith MA, Monteiro MJ. Identification of 
ubiquilin, a novel presenilin interactor that increases presenilin 
protein accumulation. J Cell Biol 2000; 151(4): 847-62. 
[37] Bertram L, Hiltunen M, Parkinson M, et al. Family-based 
association between Alzheimer's disease and variants in UBQLN1. 
N Engl J Med 2005; 352(9): 884-94. 
[38] Li A, Xie Z, Dong Y, McKay KM, McKee ML, Tanzi RE. Isolation 
and characterization of the Drosophila ubiquilin ortholog dUbqln: 
in vivo interaction with early-onset alzheimer disease genes. Hum 
Mol Genet 2007; 16(21): 2626-39. 
[39] Ganguly A, Feldman RM, Guo M. ubiquilin antagonizes presenilin 
and promotes neurodegeneration in Drosophila. Hum Mol Genet 
2008; 17(2): 293-302. 
[40] Gross GG, Feldman RM, Ganguly A, Wang J, Yu H, Guo M. Role 
of X11 and ubiquilin as in vivo regulators of the amyloid precursor 
protein in Drosophila. PLoS ONE 2008; 3(6): e2495. 
[41] van de Hoef DL, Hughes J, Livne-Bar I, Garza D, Konsolaki M, 
Boulianne GL. Identifying genes that interact with Drosophila 
presenilin and amyloid precursor protein. Genesis 2009 Apr; 47(4): 
246-60. 
[42] Mahoney MB, Parks AL, Ruddy DA, et al. Presenilin-based genetic 
screens in Drosophila melanogaster identify novel notch pathway 
modifiers. Genetics 2006; 172(4): 2309-24. 
[43] Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y. 
Dissecting the pathological effects of human Abeta40 and Abeta42 
in Drosophila: a potential model for Alzheimer's disease. Proc Natl 
Acad Sci U S A 2004; 101(17): 6623-8. 
[44] Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for 
studying Alzheimer's Abeta42-induced toxicity in Drosophila 
melanogaster. Mol Cell Neurosci 2004; 26(3): 365-75. 
[45] Crowther DC, Kinghorn KJ, Miranda E, et al. Intraneuronal Abeta, 
non-amyloid aggregates and neurodegeneration in a Drosophila 
model of Alzheimer's disease. Neuroscience 2005; 132(1): 123-35. 
[46] Casas-Tinto S, Zhang Y, Sanchez-Garcia J, Gomez-Velazquez M, 
Rincon-Limas DE, Fernandez-Funez P. The ER stress factor XBP1s 
prevents Amyloid-ss neurotoxicity. Hum Mol Genet 2011; 20(11): 
2144-60. 
[47] Luheshi LM, Tartaglia GG, Brorsson AC, et al. Systematic in vivo
analysis of the intrinsic determinants of amyloid Beta 
pathogenicity. PLoS Biol 2007; 5(11): e290. 
[48] Iijima K, Chiang HC, Hearn SA, et al. Abeta42 mutants with 
different aggregation profiles induce distinct pathologies in 
Drosophila. PLoS ONE 2008; 3(2): e1703. 
[49] Nerelius C, Sandegren A, Sargsyan H, et al. Alpha-helix targeting 
reduces amyloid-beta peptide toxicity. Proc Natl Acad Sci U S A 
2009; 106(23): 9191-6. 
[50] Iijima-Ando K, Iijima K. Transgenic Drosophila models of 
Alzheimer's disease and tauopathies. Brain Struct Funct 2010; 
214(2-3): 245-62. 
[51] Khurana V. Modeling Tauopathy in the fruit fly Drosophila 
melanogaster. J Alzheimers Dis 2008; 15(4): 541-53. 
[52] Wittmann CW, Wszolek MF, Shulman JM, et al. Tauopathy in 
Drosophila: neurodegeneration without neurofibrillary tangles. 
Science 2001; 293(5530): 711-4. 
[53] Williams DW, Tyrer M, Shepherd D. Tau and tau reporters disrupt 
central projections of sensory neurons in Drosophila. J Comp 
Neurol 2000; 428(4): 630-40. 
[54] Chen X, Li Y, Huang J, et al. Study of tauopathies by comparing 
Drosophila and human tau in Drosophila. Cell Tissue Res 2007; 
329(1): 169-78. 
[55] Shulman JM, Feany MB. Genetic modifiers of tauopathy in 
Drosophila. Genetics 2003; 165(3): 1233-42. 
[56] Blard O, Feuillette S, Bou J, et al. Cytoskeleton proteins are 
modulators of mutant tau-induced neurodegeneration in Drosophila. 
Hum Mol Genet 2007; 16(5): 555-66. 
[57] Fulga TA, Elson-Schwab I, Khurana V, et al. Abnormal bundling 
and accumulation of F-actin mediates tau-induced neuronal 
degeneration in vivo. Nat Cell Biol 2007; 9(2): 139-48. 
[58] Khurana V, Lu Y, Steinhilb ML, Oldham S, Shulman JM, Feany 
MB. TOR-mediated cell-cycle activation causes neurodegeneration 
in a Drosophila tauopathy model. Curr Biol 2006; 16(3): 230-41. 
[59] Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 
373(9680): 2055-66. 
[60] Cookson MR. alpha-Synuclein and neuronal cell death. Mol 
Neurodegener 2009; 4: 9. 
[61] Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. The genetics 
of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 
2009; 19(3): 254-65. 
[62] Botella JA, Bayersdorfer F, Gmeiner F, Schneuwly S. Modelling 
Parkinson's disease in Drosophila. Neuromolecular Med 2009; 
11(4): 268-80. 
[63] Ambegaokar SS, Roy B, Jackson GR. Neurodegenerative models in 
Drosophila: polyglutamine disorders, Parkinson disease, and 
amyotrophic lateral sclerosis. Neurobiol Dis 2010; 40(1): 29-39. 
[64] Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. 
Chaperone suppression of alpha-synuclein toxicity in a Drosophila 
model for Parkinson's disease. Science 2002; 295(5556): 865-8. 
[65] Pesah Y, Burgess H, Middlebrooks B, et al. Whole-mount analysis 
reveals normal numbers of dopaminergic neurons following 
misexpression of alpha-Synuclein in Drosophila. Genesis 2005; 
41(4): 154-9. 
[66] Botella JA, Bayersdorfer F, Schneuwly S. Superoxide dismutase 
overexpression protects dopaminergic neurons in a Drosophila 
model of Parkinson's disease. Neurobiol Dis 2008; 30(1): 65-73. 
[67] Trinh K, Moore K, Wes PD, et al. Induction of the phase II 
detoxification pathway suppresses neuron loss in Drosophila 
models of Parkinson's disease. J Neurosci 2008; 28(2): 465-72. 
[68] Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany 
MB. Aggregated alpha-synuclein mediates dopaminergic 
neurotoxicity in vivo. J Neurosci 2007; 27(12): 3338-46. 
[69] Karpinar DP, Balija MB, Kugler S, et al. Pre-fibrillar alpha-
synuclein variants with impaired beta-structure increase 
neurotoxicity in Parkinson's disease models. Embo J 2009; 28(20): 
3256-68. 
[70] Williams AJ, Paulson HL. Polyglutamine neurodegeneration: 
protein misfolding revisited. Trends Neurosci 2008; 31(10): 521-8. 
[71] Marsh JL, Thompson LM. Drosophila in the study of 
neurodegenerative disease. Neuron 2006; 52(1): 169-78. 
[72] Ross CA, Tabrizi SJ. Huntington's disease: from molecular 
pathogenesis to clinical treatment. Lancet Neurol 2011; 10(1): 83-
98. 
[73] Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors 
arrest polyglutamine-dependent neurodegeneration in Drosophila. 
Nature 2001; 413(6857): 739-43. 
[74] Lee WC, Yoshihara M, Littleton JT. Cytoplasmic aggregates trap 
polyglutamine-containing proteins and block axonal transport in a 
Drosophila model of Huntington's disease. Proc Natl Acad Sci U S 
A 2004; 101(9): 3224-9. 
[75] Steffan JS, Agrawal N, Pallos J, et al. SUMO modification of 
Huntingtin and Huntington's disease pathology. Science 2004; 
304(5667): 100-4. 
[76] Romero E, Cha GH, Verstreken P, et al. Suppression of 
neurodegeneration and increased neurotransmission caused by 
expanded full-length huntingtin accumulating in the cytoplasm. 
Neuron 2008; 57(1): 27-40. Fly Models of Proteinopathies  Current Pharmaceutical Design, 2012, Vol. 18, No. 8    1121
[77] Dion PA, Daoud H, Rouleau GA. Genetics of motor neuron 
disorders: new insights into pathogenic mechanisms. Nat Rev Genet 
2009; 10(11): 769-82. 
[78] Rothstein JD. Current hypotheses for the underlying biology of 
amyotrophic lateral sclerosis. Ann Neurol 2009; 65 Suppl 1: S3-9. 
[79] Elia AJ, Parkes TL, Kirby K, et al. Expression of human FALS 
SOD in motorneurons of Drosophila. Free Radic Biol Med 1999 
May; 26(9-10): 1332-8. 
[80] Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, 
Boulianne GL. Extension of Drosophila lifespan by overexpression 
of human SOD1 in motorneurons. Nat Genet 1998 Jun; 19(2): 171-
4. 
[81] Mockett RJ, Radyuk SN, Benes JJ, Orr WC, Sohal RS. Phenotypic 
effects of familial amyotrophic lateral sclerosis mutant Sod alleles 
in transgenic Drosophila. Proc Natl Acad Sci U S A 2003; 100(1): 
301-6. 
[82] Watson MR, Lagow RD, Xu K, Zhang B, Bonini NM. A drosophila 
model for amyotrophic lateral sclerosis reveals motor neuron 
damage by human SOD1. J Biol Chem 2008; 283(36): 24972-81. 
[83] Aguzzi A, Baumann F, Bremer J. The Prion's Elusive Reason for 
Being. Annu Rev Neurosci 2008; 31: 439-77. 
[84] Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998; 95(23): 
13363-83. 
[85] Rincon-Limas DE, Casas-Tinto S, Fernandez-Funez P. Exploring 
prion protein biology in flies: genetics and beyond. Prion 2010; 
4(1): 1-8. 
[86] Gavin BA, Dolph MJ, Deleault NR, et al. Accelerated accumulation 
of misfolded prion protein and spongiform degeneration in a 
Drosophila model of Gerstmann-Straussler-Scheinker syndrome. J 
Neurosci 2006; 26(48): 12408-14. 
[87] Choi JK, Jeon YC, Lee DW, et al. A Drosophila model of GSS 
syndrome suggests defects in active zones are responsible for 
pathogenesis of GSS syndrome. Hum Mol Genet 2010; 19(22): 
4474-89. 
[88] Wadsworth JD, Collinge J. Update on human prion disease. 
Biochim Biophys Acta 2007; 1772(6): 598-609. 
[89] Fernandez-Funez P, Casas-Tinto S, Zhang Y, et al. In vivo
generation of neurotoxic prion protein: role for hsp70 in 
accumulation of misfolded isoforms. PLoS Genet 2009; 5(6): 
e1000507. 
[90] Fernandez-Funez P, Zhang Y, Casas-Tinto S, Xiao X, Zou WQ, 
Rincon-Limas DE. Sequence-dependent prion protein misfolding 
and neurotoxicity. J Biol Chem 2010; 285(47): 36897-908. 
[91] Khan MQ, Sweeting B, Mulligan VK, et al. Prion disease 
susceptibility is affected by beta-structure folding propensity and 
local side-chain interactions in PrP. Proc Natl Acad Sci U S A 
2010; 107(46): 19808-13. 
[92] Fernandez-Funez P, Zhang Y, Sanchez-Garcia J, Jensen K, Zou W, 
Rincon-Limas DE. Pulling rabbits to reveal the secrets of the prion 
protein. Commun Integr Biol 2011; 4(3). 
[93] Jackson GR, Wiedau-Pazos M, Sang TK, et al. Human wild-type 
tau interacts with wingless pathway components and produces 
neurofibrillary pathology in Drosophila. Neuron 2002; 34(4): 509-
19. 
[94] Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J. 
Prion propagation and toxicity in vivo occur in two distinct 
mechanistic phases. Nature 2011 Feb 24; 470(7335): 540-2. 
[95] Gouras GK, Tsai J, Naslund J, et al. Intraneuronal Abeta42 
accumulation in human brain. Am J Pathol 2000; 156(1): 15-20. 
[96] Bilen J, Bonini NM. Genome-wide screen for modifiers of ataxin-3 
neurodegeneration in Drosophila. PLoS Genet 2007; 3(10): 1950-
64. 
[97] Cao W, Song HJ, Gangi T, et al. Identification of novel genes that 
modify phenotypes induced by Alzheimer's beta-amyloid 
overexpression in Drosophila. Genetics 2008; 178(3): 1457-71. 
[98] Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, 
Zoghbi HY. Chaperone suppression of aggregation and altered 
subcellular proteasome localization imply protein misfolding in 
SCA1. Nat Genet 1998; 19(2): 148-54. 
[99] Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, 
Bonini NM. Suppression of polyglutamine-mediated 
neurodegeneration in Drosophila by the molecular chaperone 
HSP70. Nat Genet 1999; 23(4): 425-8. 
[100] Cummings CJ, Sun Y, Opal P, et al. Over-expression of inducible 
HSP70 chaperone suppresses neuropathology and improves motor 
function in SCA1 mice. Hum Mol Genet 2001; 10(14): 1511-8. 
[101] Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 
Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem 
2004; 279(24): 25497-502. 
[102] Ron D, Walter P. Signal integration in the endoplasmic reticulum 
unfolded protein response. Nat Rev Mol Cell Biol 2007; 8(7): 519-
29. 
[103] Yoshida H. ER stress and diseases. Febs J 2007; 274(3): 630-58. 
[104] Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in 
a temporally ordered phosphorylation process that confers tau 
toxicity in Drosophila. Cell 2004; 116(5): 671-82. 
[105] Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. 
Tau phosphorylation sites work in concert to promote neurotoxicity 
in vivo. Mol Biol Cell 2007; 18(12): 5060-8. 
[106] Steinhilb ML, Dias-Santagata D, Mulkearns EE, et al. S/P and T/P 
phosphorylation is critical for tau neurotoxicity in Drosophila. J 
Neurosci Res 2007; 85(6): 1271-8. 
[107] Chatterjee S, Sang TK, Lawless GM, Jackson GR. Dissociation of 
tau toxicity and phosphorylation: role of GSK-3beta, MARK and 
Cdk5 in a Drosophila model. Hum Mol Genet 2009; 18(1): 164-77. 
[108] Chen HK, Fernandez-Funez P, Acevedo SF, et al. Interaction of 
Akt-phosphorylated ataxin-1 with 14-3-3 mediates 
neurodegeneration in spinocerebellar ataxia type 1. Cell 2003; 
113(4): 457-68. 
[109] Emamian ES, Kaytor MD, Duvick LA, et al. Serine 776 of ataxin-1 
is critical for polyglutamine-induced disease in SCA1 transgenic 
mice. Neuron 2003; 38(3): 375-87. 
[110] Chen L, Feany MB. Alpha-synuclein phosphorylation controls 
neurotoxicity and inclusion formation in a Drosophila model of 
Parkinson disease. Nat Neurosci 2005; 8(5): 657-63. 
[111] Chen L, Periquet M, Wang X, et al. Tyrosine and serine 
phosphorylation of alpha-synuclein have opposing effects on 
neurotoxicity and soluble oligomer formation. J Clin Invest 2009; 
119(11): 3257-65. 
[112] Tan L, Schedl P, Song HJ, Garza D, Konsolaki M. The Toll--
>NFkappaB signaling pathway mediates the neuropathological 
effects of the human Alzheimer's Abeta42 polypeptide in 
Drosophila. PLoS One 2008; 3(12): e3966. 
[113] Branco J, Al-Ramahi I, Ukani L, et al. Comparative analysis of 
genetic modifiers in Drosophila points to common and distinct 
mechanisms of pathogenesis among polyglutamine diseases. Hum 
Mol Genet 2008; 17(3): 376-90. 
[114] Lim J, Crespo-Barreto J, Jafar-Nejad P, et al. Opposing effects of 
polyglutamine expansion on native protein complexes contribute to 
SCA1. Nature 2008; 452(7188): 713-8. 
[115] Lessing D, Bonini NM. Polyglutamine genes interact to modulate 
the severity and progression of neurodegeneration in Drosophila. 
PLoS Biol 2008; 6(2): e29. 
[116] Al-Ramahi I, Perez AM, Lim J, et al. dAtaxin-2 mediates expanded 
Ataxin-1-induced neurodegeneration in a Drosophila model of 
SCA1. PLoS Genet 2007; 3(12): e234. 
[117] Mallik M, Lakhotia SC. Modifiers and mechanisms of multi-system 
polyglutamine neurodegenerative disorders: lessons from fly 
models. J Genet 2010; 89(4): 497-526. 
[118] Kaltenbach LS, Romero E, Becklin RR, et al. Huntingtin 
interacting proteins are genetic modifiers of neurodegeneration. 
PLoS Genet 2007; 3(5): e82. 
[119] Miller JP, Holcomb J, Al-Ramahi I, et al. Matrix metalloproteinases 
are modifiers of huntingtin proteolysis and toxicity in Huntington's 
disease. Neuron 2010; 67(2): 199-212. 
[120] Doumanis J, Wada K, Kino Y, Moore AW, Nukina N. RNAi 
screening in Drosophila cells identifies new modifiers of mutant 
huntingtin aggregation. PLoS ONE 2009; 4(9): e7275. 
[121] Zhang S, Binari R, Zhou R, Perrimon N. A genomewide RNA 
interference screen for modifiers of aggregates formation by mutant 
Huntingtin in Drosophila. Genetics 2010; 184(4): 1165-79. 
[122] Rival T, Page RM, Chandraratna DS, et al. Fenton chemistry and 
oxidative stress mediate the toxicity of the beta-amyloid peptide in 
a Drosophila model of Alzheimer's disease. Eur J Neurosci 2009 
Apr; 29(7): 1335-47. 
[123] Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks 
ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's 
models. Science 2006; 313(5785): 324-8. 
[124] Bell AJ, McBride SM, Dockendorff TC. Flies as the ointment: 
Drosophila modeling to enhance drug discovery. Fly (Austin) 2009; 
3(1): 39-49. 1122    Current Pharmaceutical Design, 2012, Vol. 18, No. 8  Rincon-Limas et al. 
[125] Rand MD. Drosophotoxicology: the growing potential for 
Drosophila in neurotoxicology. Neurotoxicol Teratol 2010; 32(1): 
74-83. 
[126] Mayr LM, Bojanic D. Novel trends in high-throughput screening. 
Curr Opin Pharmacol 2009; 9(5): 580-8. 
[127] Sarantseva S, Timoshenko S, Bolshakova O, et al. Apolipoprotein 
E-mimetics inhibit neurodegeneration and restore cognitive 
functions in a transgenic Drosophila model of Alzheimer's disease. 
PLoS One 2009; 4(12): e8191. 
[128] Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR 
induces autophagy and reduces toxicity of polyglutamine 
expansions in fly and mouse models of Huntington disease. Nat 
Genet 2004; 36(6): 585-95. 
[129] McConoughey SJ, Basso M, Niatsetskaya ZV, et al. Inhibition of 
transglutaminase 2 mitigates transcriptional dysregulation in models 
of Huntington disease. EMBO Mol Med 2010; 2(9): 349-70. 
[130] Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL. 
ERK activation by the polyphenols fisetin and resveratrol provides 
neuroprotection in multiple models of Huntington's disease. Hum 
Mol Genet 2011; 20(2): 261-70. 
[131] Gohil VM, Offner N, Walker JA, et al. Meclizine is neuroprotective 
in models of Huntington's disease. Hum Mol Genet 2011; 20(2): 
294-300. 
[132] Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors 
rescue alpha-synuclein-mediated toxicity in models of Parkinson's 
disease. Science 2007; 317(5837): 516-9. 
[133] Luthi-Carter R, Taylor DM, Pallos J, et al. SIRT2 inhibition 
achieves neuroprotection by decreasing sterol biosynthesis. Proc 
Natl Acad Sci U S A 2010; 107(17): 7927-32. 
[134] Auluck PK, Bonini NM. Pharmacological prevention of Parkinson 
disease in Drosophila. Nat Med 2002; 8(11): 1185-6. 
[135] Merdes G, Soba P, Loewer A, Bilic MV, Beyreuther K, Paro R. 
Interference of human and Drosophila APP and APP-like proteins 
with PNS development in Drosophila. Embo J 2004; 23(20): 4082-
95. 
[136] Fossgreen A, Bruckner B, Czech C, Masters CL, Beyreuther K, 
Paro R. Transgenic Drosophila expressing human amyloid 
precursor protein show gamma-secretase activity and a blistered-
wing phenotype. Proc Natl Acad Sci U S A 1998; 95(23): 13703-8. 
[137] Seidner GA, Ye Y, Faraday MM, Alvord WG, Fortini ME. 
Modeling clinically heterogeneous presenilin mutations with 
transgenic Drosophila. Curr Biol 2006; 16(10): 1026-33. 
[138] Guo M, Hong EJ, Fernandes J, Zipursky SL, Hay BA. A reporter 
for amyloid precursor protein gamma-secretase activity in 
Drosophila. Hum Mol Genet 2003; 12(20): 2669-78. 
[139] Schilling S, Zeitschel U, Hoffmann T, et al. Glutaminyl cyclase 
inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-
like pathology. Nat Med 2008; 14(10): 1106-11. 
[140] Murray MJ, Merritt DJ, Brand AH, Whitington PM. In vivo
dynamics of axon pathfinding in the Drosophilia CNS: a time-lapse 
study of an identified motorneuron. J Neurobiol 1998; 37(4): 607-
21. 
[141] Mershin A, Pavlopoulos E, Fitch O, Braden BC, Nanopoulos DV, 
Skoulakis EM. Learning and memory deficits upon TAU 
accumulation in Drosophila mushroom body neurons. Learn Mem 
2004; 11(3): 277-87. 
[142] Mudher A, Shepherd D, Newman TA, et al. GSK-3beta inhibition 
reverses axonal transport defects and behavioural phenotypes in 
Drosophila. Mol Psychiatry 2004; 9(5): 522-30. 
[143] Folwell J, Cowan CM, Ubhi KK, et al. Abeta exacerbates the 
neuronal dysfunction caused by human tau expression in a 
Drosophila model of Alzheimer's disease. Exp Neurol 2010; 223(2): 
401-9. 
[144] Mugat B, Parmentier ML, Bonneaud N, Chan HY, Maschat F. 
Protective role of Engrailed in a Drosophila model of Huntington's 
disease. Hum Mol Genet 2008; 17(22): 3601-16. 
[145] Satterfield TF, Jackson SM, Pallanck LJ. A Drosophila homolog of 
the polyglutamine disease gene SCA2 is a dosage-sensitive 
regulator of actin filament formation. Genetics 2002; 162(4): 1687-
702. 
[146] Matsumoto M, Yada M, Hatakeyama S, et al. Molecular clearance 
of ataxin-3 is regulated by a mammalian E4. Embo J 2004; 23(3): 
659-69. 
[147] Warrick JM, Morabito LM, Bilen J, et al. Ataxin-3 suppresses 
polyglutamine neurodegeneration in Drosophila by a ubiquitin-
associated mechanism. Mol Cell 2005; 18(1): 37-48. 
[148] Latouche M, Lasbleiz C, Martin E, et al. A conditional pan-
neuronal Drosophila model of spinocerebellar ataxia 7 with a 
reversible adult phenotype suitable for identifying modifier genes. J 
Neurosci 2007; 27(10): 2483-92. 
[149] Charroux B, Freeman M, Kerridge S, Baonza A. Atrophin 
contributes to the negative regulation of epidermal growth factor 
receptor signaling in Drosophila. Dev Biol 2006; 291(2): 278-90. 
[150] Chan HY, Warrick JM, Andriola I, Merry D, Bonini NM. Genetic 
modulation of polyglutamine toxicity by protein conjugation 
pathways in Drosophila. Hum Mol Genet 2002; 11(23): 2895-904. 
[151] Takeyama K, Ito S, Yamamoto A, et al. Androgen-dependent 
neurodegeneration by polyglutamine-expanded human androgen 
receptor in Drosophila. Neuron 2002; 35(5): 855-64. 
Received: October 4, 2011   Accepted: December 19, 2011